Aimee S. Weisner
About Aimee S. Weisner
Aimee S. Weisner, age 57, has served as an independent director of LENSAR, Inc. since February 2021. She is a former corporate vice president and general counsel at Edwards Lifesciences and previously held senior legal and administrative roles at Advanced Medical Optics and Allergan; she holds a B.A. from California State University, Fullerton and a J.D. from Loyola Law School, Los Angeles . Her core credentials center on medical device legal, compliance, corporate governance, risk management, and transactions .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Edwards Lifesciences | Corporate Vice President, General Counsel | Jan 2011 – Jul 2019 | Led global legal/compliance; governance and risk oversight |
| Advanced Medical Optics (acquired by Abbott) | EVP, Administration; Secretary | Jun 2002 – May 2009 | Executive leadership; governance, HR, internal audit interfaces |
| Allergan | VP, Assistant General Counsel & Assistant Secretary | Jan 1998 – Jun 2002 | Corporate legal leadership; IP and regulatory exposure |
| O’Melveny & Myers LLP | Associate | Early career | Foundational legal training |
External Roles
| Company | Role | Tenure | Notes |
|---|---|---|---|
| Glaukos Corporation (NYSE: GKOS) | Director | Jul 2014 – Present | Ophthalmic medtech/pharma; ongoing board service |
| STAAR Surgical (Nasdaq: STAA) | Director | Jun 2022 – Jun 2025 | Ophthalmic implantable lenses; tenure ended 2025 |
| Oyster Point Pharma (Nasdaq: OYST) | Director | Oct 2019 – Jan 2023 | Ocular surface therapies; ended on acquisition |
Board Governance
- Independence and tenure: The Board determined Ms. Weisner is independent under Nasdaq rules; she has served since 2021 .
- Committee assignments: Member, Compensation Committee; not a chair. Current chairs: Audit (O’Farrell), Compensation (Lindstrom), Nominating & Corporate Governance (Winer) .
- Attendance: In 2024, Board met 7x; Audit 4x; Compensation 2x; Nominating 2x. Each incumbent director attended at least 75% of applicable meetings; all directors attended the 2024 Annual Meeting .
- Executive sessions: Independent directors meet privately at least twice a year; Chair presides .
- Governance infrastructure: Formal Corporate Governance Guidelines; committee charters; Code of Conduct; anti-hedging policy for directors/officers/employees .
Fixed Compensation
| Component | Amount | Period/Grant | Terms |
|---|---|---|---|
| Fees Earned (Cash) | $84,082 | FY 2024 | Includes committee membership fees and $28,280 cash in lieu of equity as noted in footnote (1) |
| Stock Awards (RSUs) – 2024 | $71,720 (grant-date fair value) | FY 2024 | Annual director RSU; valuation per ASC 718 |
| Standard Director Retainers | Board $50,000; Chair $75,000; Audit Chair $20,000; Compensation Chair $15,000; Nominating Chair $9,000; Audit Member $10,000; Compensation Member $7,000; Nominating Member $4,500 | Program terms | Non-employee director compensation schedule |
Performance Compensation
| Award | Quantity/Value | Grant Date | Vesting/Performance | Notes |
|---|---|---|---|---|
| Annual RSU (all non-employee directors) | 7,374 RSUs | May 23, 2025 | Vests 100% on first anniversary of grant; accelerates upon change-in-control, death or disability | SEC Form 4 filed May 28, 2025 reflecting 5/23/2025 award |
No director performance metrics (e.g., revenue, EBITDA, TSR) are tied to Ms. Weisner’s director compensation; director equity is time-based. Change-in-control acceleration applies to director awards .
Other Directorships & Interlocks
| Relationship | Detail | Governance Implication |
|---|---|---|
| GKOS board service | Active director at Glaukos (ophthalmic medtech) | Industry expertise; potential information networks in ophthalmology; no disclosed related-party transactions between LNSR and GKOS |
| Prior STAA board service | Director until Jun 2025 | Sector adjacency to LNSR (ophthalmic implants); no disclosed related-party transactions |
| Link’s prior GKOS service | LNSR Chair Dr. Link previously on GKOS board (2001–2021) | Historical network linkage; monitor for any perceived influence channels; no conflicts disclosed |
| North Run influence | Two North Run designees (Ellis, Hammer) on Board; North Run owns ~55% common and has preferred/warrants per 2023 financing | Board composition concentrated; underscores importance of independent directors (incl. Weisner) in committee oversight |
Expertise & Qualifications
- Deep in-house legal and compliance leadership across medical device and pharma; strengths in regulatory, reimbursement, IP, corporate governance, risk management, transactions, HR, and internal audit .
- Brings ophthalmic sector experience and public company board governance to LNSR .
Equity Ownership
| Measure | Amount | As-of | Notes |
|---|---|---|---|
| Total Beneficial Ownership (Common) | 196,905 shares; 1.6% of common outstanding | Oct 24, 2025 | Includes shares acquirable within 60 days via options/RSUs per SEC rules |
| Options Outstanding | 111,332 shares underlying stock options | Dec 31, 2024 | Director options outstanding per year-end table |
| RSUs Outstanding | 22,000 RSUs | Dec 31, 2024 | Director RSUs outstanding per year-end table |
| Hedging/Pledging | Hedging prohibited by policy; pledging not disclosed | Policy level | Insider Trading Policy bans hedging transactions |
Governance Assessment
- Independence and engagement: Confirmed independent; compensation committee membership provides direct oversight of pay policies; 2024 attendance ≥75% across Board/committees supports engagement .
- Alignment: Meaningful equity exposure via options and RSUs; 2025 annual RSU grant aligns interests; director awards accelerate on change-in-control (standard for many small-cap medtechs) .
- Compensation structure: Mix of cash and time-based RSUs; no performance-based director metrics; cash-in-lieu for part of equity in 2024 noted ($28,280) – not uncommon but should be monitored relative to alignment goals .
- Conflicts/related parties: No related-party transactions disclosed involving Ms. Weisner. Broader board-level related party exposure exists via North Run’s investment and board designees; emphasizes need for independent committee efficacy, which includes Weisner on Compensation .
- Signals for investor confidence: Robust governance infrastructure (charters, guidelines, code; anti-hedging), independent audit chair and compensation chair; use of independent compensation consultant (Pay Governance) with no conflicts in 2024 . Executive-session cadence supports independent oversight .
Red flags to monitor
- Board concentration: North Run ownership/rights and two designees; potential influence on strategic decisions and capital allocation; continued affirmation of independence and robust committee practices mitigates risk .
- Change-in-control acceleration on director equity: Standard but can be perceived as misaligned if M&A premiums are dominant; transparency is present .
- No disclosed pledging policy: Hedging is prohibited; pledging not addressed explicitly—monitor disclosures .
Appendix: Committee Matrix (LNSR Board)
| Director | Audit | Compensation | Nominating & Corporate Governance |
|---|---|---|---|
| Aimee S. Weisner | — | Member | — |
| Elizabeth G. O’Farrell | Chair | — | — |
| Richard L. Lindstrom, MD | Member | Chair | Member |
| William J. Link, PhD | Member | Member | Member |
| Gary M. Winer | Member | Member | Chair |
| Thomas B. Ellis | — | — | Member |
| Todd B. Hammer | — | Member | — |
| Nicholas T. Curtis | — | — | — |
Insider Trades (Disclosure References)
| Date Filed | Period of Report | Form | Transaction | Quantity |
|---|---|---|---|---|
| May 28, 2025 | May 23, 2025 | Form 4 | Annual RSU award (director grant) | 7,374 RSUs per program; vests 1 year |